Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk

Preemptive targeted pharmacogenetic testing of candidate variations in DPYD is currently being used to limit toxicity associated with fluoropyrimidines. The use of innovative next generation sequencing (NGS) approaches could unveil additional rare (minor allele frequency <1%) genetic risk variant...

Descripción completa

Detalles Bibliográficos
Autores principales: De Mattia, Elena, Silvestri, Marco, Polesel, Jerry, Ecca, Fabrizio, Mezzalira, Silvia, Scarabel, Lucia, Zhou, Yitian, Roncato, Rossana, Lauschke, Volker M., Calza, Stefano, Spina, Michele, Puglisi, Fabio, Toffoli, Giuseppe, Cecchin, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editions Scientifiques Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463069/
https://www.ncbi.nlm.nih.gov/pubmed/36063648
http://dx.doi.org/10.1016/j.biopha.2022.113644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463069/
https://www.ncbi.nlm.nih.gov/pubmed/36063648
http://dx.doi.org/10.1016/j.biopha.2022.113644

Ejemplares similares